KRAS and pancreatic intraductal papillary-mucinous neoplasm: Furthermore, Arid1a deletion in mice with pancreatic expression of activated KRAS resulted in IPMN that progressed to PDAC [49,82].Mechanistically, Arid1a deletion inhibited the mTOR pathway, suppressed SOX9 expression, and led to dedifferentiation of pancreatic ductal cells [82].